TRIAL DETAIL
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Phase I/II Study of PDR001 in Patients With Advanced Malignancies |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Active, not recruiting |
|||
Phase: |
1/2 |
Start Date 04/01/2015 |
Age of Trial (yrs) 9.1 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PD-1 Inhibitor |
|||
Strategy: |
Stimulate the immune system |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CPDR001X2101, 2014-003929-17 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Novartis Pharmaceuticals 1-888-669-6682
+41613241111 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
| Novartis R&D page |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Baltimore |
MD |
21231 |
USA |
||
55 Fruit Street |
Boston |
MA |
02114 |
USA |
|
Portland |
OR |
97239 |
USA |
||
3322 West End Avenue |
Nashville |
TN |
37203 |
USA |
|
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
2000 Circle of Hope |
Salt Lake City |
UT |
84103 |
USA |
|
Toronto |
ON |
Canada |
|||
Villejuif |
Val de Narne |
94805 |
France |
||
Amsterdam |
1066 CX |
Netherlands |
|||
Leiden |
2300 RC |
Netherlands |
|||
119-129 |
Barcelona |
08035 |
Spain |
||
Taipei |
Taiwan |
||||
Toulouse |
31052 |
France |
|||
Madrid |
28050 |
Spain |
|||
Tainan City |
Taiwan |
||||
Paris |
France |
||||
Ulm |
89081 |
Germany |
|||
Oslo |
N-0310 |
Norway |
|||
Milan |
20132 |
Italy |
|||
Napoli |
80131 |
Italy |